Emergent BioSolutions | EBS - Cost Of Sales

Stock Price
10.93
Daily Change
-0.06 -0.55%
Monthly
-4.96%
Yearly
41.76%
Q1 Forecast
10.65

Emergent BioSolutions reported $381.2M in Cost of Sales for its fiscal quarter ending in June of 2023.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Akebia Therapeutics USD 8.13M 2.41M Mar/2025
ALKERMES USD 51.59M 2.13M Sep/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amarin USD 16.89M 18.51M Mar/2025
ANI Pharmaceuticals USD 116.02M 18.12M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Coherus Biosciences USD 2.65M 31.2M Mar/2025
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Exact Sciences USD 266.81M 18.18M Sep/2025
Exelixis USD 26.48M 7.91M Dec/2025
Glaxosmithkline GBP 3.01B 853.01M Sep/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Lexicon Pharmaceuticals USD 17.81M 3.41M Jun/2024
Lonza CHF 2.28B 189M Jun/2025
Merck USD 3.32B 531M Dec/2025
Moderna USD 452M 245M Dec/2025
Myriad Genetics USD 61.9M 600K Sep/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Pacira USD 48.6M 6.59M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
United Therapeutics USD 100.9M 74.3M Sep/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Xoma 116K 112.7K Jun/2024